Last reviewed · How we verify
NCT06977412
The Application Value of Spectral CT in the Accurate Staging of Breast Cancer
NA trial testing To explore the value of spectral CT in the diagnosis and treatment of breast cancer in Breast Adenocarcinoma in 150 participants. Not yet recruiting.
31 May 2026
Quick facts
| Lead sponsor | Yunnan Cancer Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 150 |
| Start date | 1 June 2025 |
| Primary completion | 31 May 2026 |
| Estimated completion | 31 May 2026 |
Drugs / interventions tested
- To explore the value of spectral CT in the diagnosis and treatment of breast cancer
Conditions studied
- Breast Adenocarcinoma — all drugs for Breast Adenocarcinoma →
Sponsor
Yunnan Cancer Hospital
Who can join
Adults 18 to 80, female only, with Breast Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Spectral CT was used to prospectively collect medical images and clinical data related to breast cancer, evaluate the effect of image quality in the diagnosis of breast cancer, and evaluate the application value in the accurate staging of breast cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06977412
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Adenocarcinoma
Currently open trials in the same condition.
- NCT07122713 — Definitive Radiation Therapy for Inoperable Breast Cancer · NA · recruiting
- NCT07069790 — Effects of Chemotherapy Treatment on Metaboreflex, Mechanoreflex, and Baroreflex Function: PROTECT-08B Study · NA · recruiting
- NCT07389408 — A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patient · recruiting
- NCT06739655 — Preoperative Radiation Therapy and Immediate Breast Reconstruction · NA · recruiting
- NCT06671262 — Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer · Phase 2 · recruiting
Other Yunnan Cancer Hospital trials
Trials by the same sponsor.
- NCT07018505 — EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph · not yet recruiting
- NCT06977386 — The Application Value of Spectral CT in the Accurate Staging of Gastric Cancer · NA · not yet recruiting
- NCT06977399 — The Application Value of Spectral CT in the Accurate Staging of Liver Cancer · NA · not yet recruiting
- NCT06977373 — The Application Value of Spectral CT in the Accurate Staging of Colorectal Cancer · NA · not yet recruiting
- NCT07154563 — Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Ca · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06977412 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yunnan Cancer Hospital
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06977412.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing